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Histamine H1 receptor antagonists (antihistamines) are widely used for treatment of 
allergic disorders and are well-known for central nervous system (CNS) side effects such as 
drowsiness, sleepiness and impaired psychomotor performance1).  Car driving is closely 
connected with our everyday life.  There are so many reports about the effects of 
antihistamines on car driving performance but its mechanism has not been demonstrated yet. 
Recently, some functional MRI (fMRI) studies have been published on brain activities 
during simulated car driving2,3,4).  Walter and colleagues revealed that the regional 
cerebral blood flow (rCBF) increased in the sensorimotor cortex and the cerebellum, by 
comparing active and passive driving conditions.  Calhoun and colleagues demonstrated 
that car driving was able to be divided into several basic componentsand that fMRI was 
useful to investigate the neural correlates of car driving.  However, there was no functional 
neuroimaging study on the drug-induced sedation during car driving.  So we investigated 
the rCBF changes during simulated car driving after oral administration of 




Materials and Methods 
Subjects 
Fourteen healthy male volunteers, ranging 20-25 years old (mean +/- SD: 21.9 +/- 
1.8), participated in the present study.  All subjects were evaluated as right-handed based 
on the Edinburgh inventory and Chapman test.  Mean driving history of all the subjects 
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was 17 months. Written informed consent was obtained from each subject and the study 
was performed in compliance with the relevant laws and institutional guidelines.  
 
Study design 
The present study was conducted as a single-blind crossover study.  The subject 
was given one of a d-chlorpheniramine 6 mg repetab (Polaramin) or a placebo in each study. 
According to the previous report, it was estimated that the peak plasma drug concentration 
of orally-administered d-chlorpheniramine was achieved at 2 hours post-administration.  
Then, the PET investigation started approximately 2 hours after oral administration of 
d-chlorpheniramine 6 mg and so did it for placebo. 
PET scans were performed for the following three conditions: 1) resting condition 
with the eyes closed, 2) active driving condition where the subjects had to drive by their 
own, using a steering wheel and accelerating pedal, and 3) passive driving condition where 
the subjects were requested to watch the changing landscape that had been videotaped, with 
the both hands fixed on the handle and with the right leg kept on the accelerating pedal.   
 
Driving simulation 
Commercially available software (Gekisoh 99, Twilight Express Co., Tokyo, Japan) 
was used for simulated driving task. The subjects were positioned in a PET scanner, 
wearing a head mount display (HMD: Glasstron PLM-A35, SONY, Tokyo, Japan) in a 
comfortable manner.  They were able to operate the steering wheel and press the 
accelerating pedal quickly while watching landscape of driving course projected onto the 
HMD. 
 
PET measurements and data analysis 
The rCBF images were obtained using a 3D-acquisition PET scanner (SET 2400W, 
Shimadzu Co. Ltd., Japan), with an average spatial resolution of 4.5 mm the full-width 
half-maximum and with a sensitivity of a 20 cm cylindrical phantom of 48.6 k.c.p.s. 
KBq-1ml-1 . PET acquisition was performed for the duration of 70 sec.  The subject was 
injected with H2
15O of 157.8 ± 25.6 MBq (5.8 ± 0.9mCi) through the antecubital vein for 
each scan.   
The rCBF images obtained were realigned, normalized and smoothed by Statistical 
Parametric Mapping (SPM) software (SPM99; Welcome Department of Cognitive 
Neurology, London, U.K.).  T-Statistics were computed for each voxel for the 
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comparisons: 1) active driving condition or passive driving condition scan minus resting 
condition scan after oral administration of placebo or d-chlorpheniramine, 2) after oral 
d-chlorpheniramine minus placebo in condition of active driving scan.  For each 
comparison, each voxel difference with Z-value higher than 3.01, corresponding to p < 
0.001 (uncorrected), was considered as significant changes in rCBF.   
 
Results 
After oral administration of placebo, the significant increase of rCBF was found in 
the sensorimotor (Brodman Area: BA 4), premotor (BA6), parietal (BA 7, 40), temporal 
(BA 37), occipital (BA17-19) cortices and in the cerebellum, midbrain, pulvinar, globus 
pallidus medialis and cingulated gyrus during active driving compared with the resting 
condition (Fig. 1).  And the regions of increased CBF during active driving in comparison 
to the passive driving condition were nearly the same. Compared to placebo, 
d-chlorpheniramine produced significant increase of rCBF in the cerebellar vermis and 
decrease of parietal (BA 7), temporal (BA 37), occipital (BA 19) cortices and cerebellum 
hemisphere during active driving.  
 
Discussion  
Car driving is closely connected with our everyday life and needs integration of 
various brain functions such as attention to other vehicles and walkers, circumstantial 
judgment, motor programming and output, working memory, etc.  It is well-known that 
antihistamines, especially first generation antihistamines, have sedative side effects.  
These side effects are dangerous especially during operating a machine or driving a car.  
The sedative antihistamines are available more easily as over-the-counter drugs than newer 
less sedating antihistamines.  There are various methods to evaluate driving performance 
after administrating sedative drugs such as subjective sleepiness, reaction time, EEG 
changes, vehicle maintenance capability, during both actual and simulated driving.  
Walter and colleagues first measured the regional brain activity in healthy 
volunteers during simulated driving using fMRI2).  They detected the brain activation 
mainly in the visual and somatosensory cortices and in the cerebellum by contrasting active 
and passive driving conditions.  It has been demonstrated functional neuroimaging is a 
very useful tool to elucidate neural correlates of driving.  In the present study, the contrast 
between active and resting conditions and that between active and passive conditions both 
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demonstrated similar results to the previous fMRI study by Walter and colleagues2).  
Taking all these findings together, it could be concluded that H2
15O-PET gives basically the 
same results as those obtained with fMRI.  
On the other hand, rCBF responses were reduced after administration of 
d-chlorpheniramine in the parietal (BA 7), temporal (BA 37), occipital regions, that are 
considered to be the visuo-spatial pathway.  The results might suggest that 
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Fig. 1.  The significant increase of rCBF during active driving compared with resting condition 
after oral administration of placebo. 
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